This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.
Our mission is to revolutionize cancer treatment with breakthrough Tumor-Specific Immune Cytokines, turning the promise of total tumor clearance and lifelong immune protection from a laboratory concept into clinical reality.
Novel platform technologies for producing immune cytokines that target cancer cells or the tumor microenvironment, designed to induce tumor-specific immunity and eliminate tumors.
CytoCan is devoted to developing life-changing Tumor-specific Immune Cytokines (TsICs) to help patients fight cancer. We envision a near future where tumors can be completely eliminated by TsICs, and patients can be protected by immunity specific to cancer.
We have developed a novel modular platform technology for producing immune cytokines that target cancer cells or the tumor microenvironment (TME). By precisely delivering immune cytokines to specific components of the TME, such as PD-1+ T cells, we aim to stimulate these T cells with TsICs to eliminate cancer cells while minimizing the risk of unintended systemic side effects.
Probiokine: A proprietary platform anchored by a humanized IgG-binding domain. Functional antibody-like proteins can be expressed in bacteria or probiotic strains.
PD-1-Targeting Cytokines: Our technology integrates an optimized PD-1 antibody, precisely binding PD-1 epitopes and carrying potency-optimized cytokines.
We identify unmet medical needs and address difficult-to-treat cancers by designing targeted immune cytokines to eliminate cancer cells. By delivering these treatments specifically to tumor microenvironments, this new class of therapies maximizes tumor-killing efficacy while minimizing systemic and unintended side effects.
Our TsICs represent the next generation of PD-1 inhibitors. They not only block the PD-1/PD-L1 interaction but also deliver immunocytokines with optimized activity to the tumor microenvironment to enable selective activation of effector T cells.
In preclinical studies, our PD-1-targeted pipeline candidates have demonstrated complete responses in animal tumor models, achieving complete remission of drug-resistant tumors.
CytoCan is an innovative biopharmaceutical company focused on the research and development of tumor-specific immune cytokines (TsIC). Its core pipeline product is a recombinant TsIC targeting PD-1, positioned as the next generation of PD-1 inhibitor, specifically designed for cancer patients with PD-1 resistance.
By targeting PD-1, this product not only blocks the PD-1/PD-L1 interaction but also delivers immunocytokines with optimized activity to the tumor microenvironment (TME) to enable the selective activation of effector T cells. By integrating these three mechanisms of action, this TsIC has achieved complete remission of drug-resistant tumors in mouse models and is expected to overcome the clinical limitations of current PD-1 inhibitors in the future.
The company is currently advancing Investigational New Drug (IND) application preparations, with plans to submit dual IND applications in China and the United States within 18 months.
View Our Pipeline
CytoCan received seed round investment
This strategic funding will accelerate the development of our TsIC platform and advance our lead candidates toward clinical trials in both China and the United States.
Our Pipeline includes the next generation PD-1/cytokines, and HER2, EGFR and TROP targeted therapies.
Target: PD-1 inhibitor-resistant solid tumors
Target: PD-1 inhibitor-resistant solid tumors
Indications: Breast cancer, Gastric cancer
Targeting EGFR-expressing tumors with precision immune activation.
Next-gen therapy for TROP2-positive solid tumors including lung and bladder cancers.
Fusion cytokine platform delivering IL-12 directly to the tumor microenvironment.
Dual-action therapy targeting PD-L1 with localized immune stimulation.
Proprietary bacterial expression system for scalable, low-cost TsIC production.
2
Lead Candidates in IND Enabling
4+
Therapeutic Targets in Development
18
Months to Dual IND (China & USA)
100%
Complete Response in Preclinical Models
TsICs are engineered fusion proteins that combine tumor-targeting antibodies with immune-stimulating cytokines. They deliver immune activation directly to the tumor microenvironment, enhancing anti-tumor responses while reducing systemic toxicity.
Unlike traditional PD-1 inhibitors that only block immune checkpoints, our TsICs block PD-1 while simultaneously delivering optimized cytokines to re-activate T cells directly within the tumor, offering a triple mechanism of action.
Our lead programs focus on PD-1 inhibitor-resistant solid tumors, HER2-positive breast and gastric cancers, and other EGFR- and TROP2-expressing malignancies.
CytoCan is headquartered in Hangzhou, China, at Nuohua Industry Park Building A, Floor 18-19, 309 Gaoxin 11 Road, Xiaoshan District, Hangzhou City, Zhejiang.
Feel free to reach out for partnerships, inquiries, or collaboration opportunities.
Email: [email protected]
Phone: 15267088941
Address:
Nuohua Industry Park Building A, Floor 18-19,
309 Gaoxin 11 Road, Xiaoshan District,
Hangzhou City, Zhejiang, China
Notice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.
For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact [email protected] via your corporate email to cancel. We will cancel your inclusion within 3 business days.
如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系[email protected] 取消收录 我们将在3个工作日取消您的收录
Service Request: If you are other domain and want to be included, please contact [email protected]
如果您是其他域名合作 也请联系[email protected]